| Literature DB >> 28362355 |
Salwa M K Almomen1, Qiunong Guan2,3, Peihe Liang4,5, Kaidi Yang6, Ahmad M Sidiqi7,8, Adeera Levin9, Caigan Du10,11.
Abstract
Individuals living with metabolic syndrome (MetS) such as diabetes and obesity are at high risk for developing chronic kidney disease (CKD). This study investigated the beneficial effect of whole grape powder (WGP) diet on MetS-associated CKD. Obese diabetic ZSF1 rats, a kidney disease model with MetS, were fed WGP (5%, w/w) diet for six months. Kidney disease was determined using blood and urine chemical analyses, and histology. When compared to Vehicle controls, WGP intake did not change the rat bodyweight, but lowered their kidney, liver and spleen weight, which were in parallel with the lower serum glucose and the higher albumin or albumin/globin ratio. More importantly, WGP intake improved the renal function as urination and proteinuria decreased, or it prevented kidney tissue damage in these diabetic rats. The renal protection of WGP diet was associated with up-regulation of antioxidants (Dhcr24, Gstk1, Prdx2, Sod2, Gpx1 and Gpx4) and downregulation of Txnip (for ROS production) in the kidneys. Furthermore, addition of grape extract reduced H₂O₂-induced cell death of cultured podocytes. In conclusion, daily intake of WGP reduces the progression of kidney disease in obese diabetic rats, suggesting a protective function of antioxidant-rich grape diet against CKD in the setting of MetS.Entities:
Keywords: antioxidants; chronic kidney disease; dietary supplements; grape powder; metabolic syndrome; natural products
Mesh:
Substances:
Year: 2017 PMID: 28362355 PMCID: PMC5409684 DOI: 10.3390/nu9040345
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1No effect of daily intake of whole grape powder (WGP) on bodyweight gain or obesity in obese diabetic ZSF1 rats.
Organ index (organ weight/bodyweight) after six months of feeding sugar (Vehicle) or whole grape powder (WGP).
| Kidneys | Liver | Spleen | Heart | Lung | |
|---|---|---|---|---|---|
| Vehicle ( | 0.0070 ± 0.00072 | 0.0627 ± 0.00418 | 0.00135± 0.00010 | 0.00289 ± 0.00115 | 0.00356 ± 0.00096 |
| WGP ( | 0.0063 ± 0.00069 | 0.0544 ± 0.00546 | 0.00129 ± 0.00001 | 0.00251 ± 0.00022 | 0.00371 ± 0.00103 |
| 0.0127 | <0.0001 | 0.0341 | 0.2351 | 0.6880 |
* The difference between Vehicle and WGP was compared using two-tailed t-test.
Figure 2Daily intake of WGP has beneficial effect on the maintenance of blood albumin and the reduction of blood glucose in obese diabetic ZSF1 rats. The blood levels of albumin (ALB), globulin (GLOB) and glucose (GLU) were measured in randomly selected rats in Vehicle (n = 8–12) or WGP (n = 8–11) group after one, three or six months of dietary supplements. Data were presented as mean ± SD of each group. (A) Blood ALB levels. Vehicle vs. WGP: p = 0.0013 (two-way ANOVA); (B) ALB/GLOB ratio. Vehicle vs. WGP: p = 0.0092 (two-way ANOVA); (C) Blood GLU levels. Vehicle vs. WGP: p = 0.0276 (two-way ANOVA).
Figure 3Daily intake of WGP reduces urine production and proteinuria but no effect on GFR in obese diabetic ZSF1 rats. A 24-h urine sample was collected from each rat in both Vehicle (n = 15) and WGP (n = 14) at the end of six months of dietary supplements. (A) Total volume of urine production from each rat during 24 h. Vehicle vs. WGP: p = 0.0092 (one-tailed t-test); (B) Total amount of protein in 24-h urine sample of each rat. Vehicle vs. WGP: p = 0.0412 (one-tailed t-test); (C) Protein to creatinine ratio (uPCR) in the urine sample of each rat. Vehicle vs. WGP: p = 0.0084 (one-tailed t-test); (D) GFR of each rat calculated based on creatinine clearance. Vehicle vs. WGP: p = 0.3474 (one-tailed t-test). Line: mean with the standard error of the mean (SEM).
Figure 4Daily intake of WGP reduces kidney injury in obese diabetic ZSF1 rats. At the end of six months of dietary supplements, six kidneys/rats were randomly selected from each group (Vehicle vs. WGP), and kidney sections were stained with either hematoxylin and eosin (HE) or Periodic acid-Schiff (PAS). (A) Typical microscopic images of renal cortex, outer medulla and a glomerulus in each group (Vehicle: top panel; WGP: bottom panel); data showed the same area of renal cortex and outer medulla stained with either HE or PAS. PC: protein cast formation; black stars (*): damaged glomerulus (glomerular atrophy); arrows: PAS-stained mesangial expansion; (B) The glomerular atrophy was scored in at least 20 randomly selected views in two separate sections of each kidney, and was presented in average per view; data are presented as mean ± SD of each group (n = 9); vehicle vs. WGP: p = 0.0225 (two-tailed t-test); (C) The mesangial expansion was determined using a 0 to 4 scale based on the percentage of the area stained strongly with PAS; a range of 180 to 250 glomeruli were counted and averaged for each kidney. Data are presented as mean ± SD of each group (n = 9); vehicle vs. WGP: p < 0.0001 (two-tailed t-test); (D) The number of intratubular protein cast formation in each microscopic view was counted in HE-stained section, and the average number of at least 20 randomly selected views under 40× magnification represented in each kidney; data are presented as mean ± SD of each group (n = 12); vehicle vs. WGP: p = 0.0006 (two-tailed t-test); (E) Tubular dilation and atrophy were determined using a 0–4 scale based on the percentage of damaged tubules occupying an area in each microscopic view; the average of at least 30 randomly selected views under 200× magnification represented the tubular atrophy in each kidney; data are presented as mean ± SD of each group (n = 12). Vehicle vs. WGP: p = 0.0036 (two-tailed t-test).
Significant changes of oxidative stress-related gene expression in renal cortex of WGP-fed rats as compared to Vehicle controls, analyzed using PCR array.
| Gene Symbol | Gene Names | Functions | Fold Change * | |
|---|---|---|---|---|
| 24-dehydrocholesterol reductase | H2O2 scavenger, preventing H2O2-induced cell death | 4.265 | 0.00222 | |
| Cytochrome | NADPH oxidase subunit, optimizing immunity | 4.215 | 0.00875 | |
| Glutathione S-transferase kappa 1 | Cellular detoxification (lipid peroxide detoxification) | 1.1475 | 0.01279 | |
| Peroxiredoxin 2 | H2O2 and Alkyl hydroperoxide antioxidant | 1.7625 | 0.02746 | |
| Superoxide dismutase, mitochondrial | Limiting ROS detrimental effect, and moderating ROS release | 2.3375 | 0.02983 | |
| Parkinson disease (autosomal recessive, early onset) 7 | Redox-sensitive chaperone | 1.24 | 0.03723 | |
| Glutathione peroxidase 4 | H2O2, lipid peroxide and hydroperoxide reduction | 1.96 | 0.03756 | |
| Glutathione peroxidase 1 | H2O2 antioxidant | 3.235 | 0.04614 | |
| Heme oxygenase (decycling) 1 | Heme degradation to CO | −101.533 | 0.01283 | |
| Excision repair cross-complementing rodent repair deficiency, complementation group 6 | Damaged DNA repair | −3.9575 | 0.02908 | |
| Glutathione S-transferase pi 1 | Cellular detoxification | −22.4875 | 0.0405 | |
| Thioredoxin interacting protein | Increasing ROS production | −37.8825 | 0.04436 |
* Minus: decreased.
Figure 5Grape extract protects cultured podocytes from H2O2-induced cell death. Grape extract was prepared by using methanol extraction. HSMP cells (0.25 × 106 cells/well) were grown in RPMI 1640 culture medium in 24-well plates at 37 °C overnight, followed by grape extract treatment (200 mg·mL−1) in the presence or absence of H2O2 (1 μM). (A) Cell viability or apoptosis was determined by FACS analysis with Annexin-V-PE and 7-AAD staining after 24-h treatment with the grape extract. Data were represented as a typical FACS graph in each group; (B) Cell viability represented the percentage of viable cells (double-Annexin-V-PE/7-AAD negative cells in lower left quadrant). Data were presented as mean ± SD of eight separate experiments in each group. Untreated vs. H2O2, p = 0.0033 (two-tailed t-test); H2O2 vs. H2O2 + Extract, p = 0.037 (two-tailed t-test); or Extract vs. H2O2 + Extract, p = 0.2732 (two-tailed t-test).